Cambridge Nutritional Science (CNSL)

Sector:

Health Care

Index:

FTSE AIM All-Share

4.10p
   
  • Change Today:
    -0.050p
  • 52 Week High: 4.35p
  • 52 Week Low: 1.73p
  • Currency: UK Pounds
  • Shares Issued: 237.95m
  • Volume: 26,037
  • Market Cap: £9.76m

Omega Diagnostics CE-marks Covid-19 lateral flow test

By Josh White

Date: Monday 22 Mar 2021

LONDON (ShareCast) - (Sharecast News) - Medical diagnostics company Omega announced on Monday that it has CE-marked Mologic's lateral flow antigen test for Covid-19, to be sold for professional use under its 'Visitect' brand.

The AIM-traded firm said the test would provide healthcare professionals with an accurate rapid test for the detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.

It said that, having started technology transfer late in 2020, it had CE-marked the product and was now in the process of completing marketing launch for commercial roll-out, which was expected to start in April.

The company said it was already in discussion with a number of potential commercial partners looking to order the test post-launch.

It added that it was "well on its way" to establishing a lateral flow production capacity of about two million tests per week by the end of April from its Alva facility in Scotland.

That production capacity would be used to produce the Visitect-branded antigen test for sale to third-party commercial customers.

Use of the company's weekly production capacity for the supply of antigen tests under the Department of Health and Social Care contract, and the supply of other tests, was expected to have a "significant" impact on the future performance of the business.

It added that while volumes were unquantified, it was likely to result in "substantial" revenue growth in the financial year beginning 1 April.

"This is an exciting and important next step in our Covid-19 strategy as we now have the ability to supply both antigen and antibody lateral flow tests not only to the UK government but also to our commercial partners," said chief executive officer Colin King.

"Having both tests available and having built our production capacity allows us to adjust our capacity to meet the demands of the pandemic.

"We look forward with confidence that the coming year ahead will be truly transformational for Omega."

At 1207 GMT, shares in Omega Diagnostics Group were up 1.42% at 89.25p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

CNSL Market Data

Currency UK Pounds
Share Price 4.10p
Change Today -0.050p
% Change -1.20 %
52 Week High 4.35p
52 Week Low 1.73p
Volume 26,037
Shares Issued 237.95m
Market Cap £9.76m

CNSL Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value Not Available
Price Trend
88.39% above the market average88.39% above the market average88.39% above the market average88.39% above the market average88.39% above the market average
83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average83.78% above the sector average
Income Not Available
Growth Not Available

CNSL Dividends

No dividends found

Trades for 23-Jul-2024

Time Volume / Share Price
08:13 1,332 @ 4.06p
08:04 20,000 @ 4.25p
08:01 4,705 @ 4.25p

Top of Page